Anixa Biosciences Presents Phase 1 Breast Cancer Vaccine Data Showing All Major Endpoints Met
Bitget2026/11/05 14:51- Anixa Biosciences completed its breast cancer vaccine Phase 1 trial, meeting all major endpoints; Phase 2 enrollment is the next milestone.
- Among 35 patients dosed, 74% showed a protocol-specified immune response; no safety concerns were reported.
- Combining the vaccine with Keytruda produced no additional adverse effects, supporting combination use.
- Lira-cel remains in Phase 1 for ovarian cancer, with periodic data releases tied to enrollment.
- Cash and short-term investments totaled $14 million as of July 31, 2026, with no debt; last fiscal year's cash burn was $7 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
